Metabolism News and Research

Latest Metabolism News and Research

Siemens to unveil Biograph mMR system at RSNA Annual Meeting

At the 96th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 28 - December 2 in Chicago, Siemens Healthcare (Booth #822, East Building/Lakeside Center, Hall D) will unveil the Biograph mMR, the world's first integrated whole-body molecular Magnetic Resonance (MR) system with simultaneous data acquisition technology, currently undergoing clinical use testing.

20 Nov 2010

Discovery could provide new approaches to treat metabolic disorders

Scientists from the Florida campus of The Scripps Research Institute have identified a novel synthetic activator of a pair of proteins that belong to a protein family playing key roles in human metabolism and immune function. The discovery could provide new and potentially more effective therapeutic approaches to diseases ranging from diabetes to osteoporosis.

20 Nov 2010

Merck wins third FOSAMAX bellwether trial

Merck & Co., Inc. today said a federal court jury in New York found in its favor in the Graves v. Merck case, rejecting the claims of a Florida woman who blamed her dental and jaw related problems on her FOSAMAX use. With today's verdict, Merck has won three of the first four bellwether cases in the FOSAMAX litigation.

20 Nov 2010

Marshall Edwards receives non-compliance notice from NASDAQ

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today that it was notified on November 16, 2010 by the Listing Qualifications Staff of The NASDAQ Stock Market that, due to the Company's non-compliance with the minimum $10 million stockholders' equity requirement for continued listing on The NASDAQ Global Market, as set forth in Listing Rule 5450(b)(1), the Company's common stock is subject to delisting unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel.

20 Nov 2010

Glenn Foundation awards $60,000 grant to Scripps' scientist for biomedical research

While scientists depend on grants for their research, applying for them is a long and frequently frustrating process. For one Scripps Research Institute scientist, however, the process was shorter.

19 Nov 2010

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Cough medicine could be used as way of predicting how well individual patients metabolise tamoxifen used in the treatment of their breast cancer, according to new research presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin today

19 Nov 2010

PAREXEL reaches milestone in early phase studies

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.

From Parexel 18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented two posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics," in Berlin, Germany.

18 Nov 2010

New pharmacogenetic test enables a personalized medicine approach

Luminex Corporation, today announced that it has commercially launched its first pharmacogenetic test, the xTAG CYP2D6 Kit, which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

From Luminex 17 Nov 2010

NT-proBNP guided heart failure care associated with reduced cardiovascular events

Roche and study investigators from Harvard University and Massachusetts General Hospital announced today that in the PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP guided heart failure care was independently associated with a significant reduction in total cardiovascular events, the primary composite endpoint of the study, which included worsening heart failure, heart failure hospitalization and cardiovascular related death

From Roche Sequencing and Life Science 17 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. announced today that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. Researchers at The University of Texas (UT) Southwestern Medical Center will conduct the study.

17 Nov 2010

Optivia, UCSF receive SBIR grant to develop transporter-based assay system

Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced that the company and the University of California, San Francisco (UCSF), have received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop an innovative system for characterizing the role transporter proteins play in the disposition of drugs by the liver.

16 Nov 2010

Isis, Xenon enter collaboration to discover and develop antisense drugs for AI

Isis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. announced today a new collaboration to discover and develop antisense drugs as novel treatments for the common disease anemia of inflammation (AI).

16 Nov 2010

UCSF, Pfizer announce partnership to accelerate translation of biomedical research

UCSF and Pfizer, Inc. have formed a new partnership to accelerate the translation of biomedical research into effective new medications and therapies for patients.

16 Nov 2010

Researchers discover circadian rhythms regulate fat metabolism

UC Irvine researchers have discovered that circadian rhythms the internal body clock regulate fat metabolism. This helps explain why people burn fat more efficiently at certain times of day and could lead to new pharmaceuticals for obesity, diabetes and energy-related illnesses.

16 Nov 2010

Study analyzes neurological recovery after hypothermia treatment in cardiac arrest patients

Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.

15 Nov 2010

Research on P450 compound I may help eliminate toxins

Chemical reactions are happening all over the place all the time on the sun, on the Earth and in our bodies. In many cases, enzymes help make these reactions occur. One family of enzymes, called cytochrome P450s (P450), is important because they help us eliminate toxins.

15 Nov 2010

Equation to calculate energetic cost of walking

Any parent that takes their kid out for a walk knows that children tire more quickly than adults, but why is that? Do kids and small adults walk differently from taller people or do they tire faster for some other reason? Peter Weyand from Southern Methodist University, USA, is fascinated by the effect that body size has on physiological function.

12 Nov 2010

Metabolism News and Research

Latest Metabolism News and Research

Siemens to unveil Biograph mMR system at RSNA Annual Meeting

Discovery could provide new approaches to treat metabolic disorders

Merck wins third FOSAMAX bellwether trial

Marshall Edwards receives non-compliance notice from NASDAQ

Glenn Foundation awards $60,000 grant to Scripps' scientist for biomedical research

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

PAREXEL reaches milestone in early phase studies

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

New pharmacogenetic test enables a personalized medicine approach

NT-proBNP guided heart failure care associated with reduced cardiovascular events

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

Optivia, UCSF receive SBIR grant to develop transporter-based assay system

Isis, Xenon enter collaboration to discover and develop antisense drugs for AI

UCSF, Pfizer announce partnership to accelerate translation of biomedical research

Researchers discover circadian rhythms regulate fat metabolism

Study analyzes neurological recovery after hypothermia treatment in cardiac arrest patients

Research on P450 compound I may help eliminate toxins

Equation to calculate energetic cost of walking

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech